Pliant Therapeutics Engages Investors in September Events
![Pliant Therapeutics Engages Investors in September Events](https://investorshangout.com/images/blog/ihnews-Pliant%20Therapeutics%20Engages%20Investors%20in%20September%20Events.jpg)
Pliant Therapeutics Engages Investors in September Events
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company, specializes in discovering and developing novel therapeutics aimed at treating fibrotic diseases. The company recently announced their participation in key investor events scheduled for September.
Upcoming Investor Events
The following events outline Pliant's strategy to engage with investors and discuss advancements in their therapeutic developments:
Wells Fargo Healthcare Conference
On September 4, executives Keith Cummings, M.D., Chief Financial Officer, and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference at 1:30 p.m. Eastern Time. This conversation will delve into the latest developments in Pliant's therapeutic offerings and the company's vision.
H.C. Wainwright 26th Annual Global Investment Conference
Following this, on September 11, Dr. Cummings and Dr. Lefebvre will again address investors during a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference at 10:30 a.m. Eastern Time, sharing insights into the company’s progress and future plans.
Cantor Global Healthcare Conference
Continuing their outreach, on September 17, attendees can tune in to hear from Bernard Coulie, M.D., Ph.D., President and CEO, alongside Dr. Cummings and Dr. Lefebvre at the Cantor Global Healthcare Conference at 10:20 a.m. Eastern Time. They will discuss the current pipeline and ongoing clinical trials.
Stifel Virtual Immunology and Inflammation Summit
Lastly, on September 18, Dr. Coulie and Dr. Cummings will participate in a fireside chat at the Stifel 2024 Virtual Immunology and Inflammation Summit at 11:00 a.m. Eastern Time, highlighting innovative approaches in tackling fibrotic diseases.
Access to Live Webcasts
Investors interested in following these discussions can access the live webcasts of these fireside chats through the Investor Relations page of Pliant Therapeutics’ website. Additionally, the recorded sessions will be available for 30 days after the events, ensuring stakeholders can stay informed of all developments.
About Pliant Therapeutics
Pliant Therapeutics is at the forefront of developing therapies aimed at fibrotic diseases. Their lead candidate, bexotegrast (PLN-74809), is an oral, small molecule that selectively inhibits integrins ?vß6 and ?vß1. This drug is currently being tested for its effectiveness against idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). The drug has been granted Fast Track Designation and Orphan Drug Designation by the FDA for both conditions, as well as similar recognitions from the European Medicines Agency.
Pliant is conducting its BEACON-IPF, an adaptive Phase 2b/3 trial for bexotegrast while also advancing a Phase 1 study for another promising candidate, PLN-101095, targeting solid tumors. Further, Pliant has received clearance to initiate a Phase 1 study for PLN-101325, a monoclonal antibody designed to address muscular dystrophies.
Ongoing Initiatives and Future Directions
As Pliant Therapeutics continues to expand its research pipeline and clinical presence, the company's innovative approach to treating fibrotic diseases positions it strongly within the biotechnology sector. The involvement in investor events not only enhances visibility but also strengthens the dialogue surrounding the company's significant contributions to therapy advancements.
Contact Information
For investor and media inquiries, please contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
Email: ir@pliantrx.com
Frequently Asked Questions
What is Pliant Therapeutics focusing on during the September events?
Pliant Therapeutics will discuss their innovative treatments for fibrotic diseases, including their lead drug, bexotegrast, at investor events.
Who are the key speakers at the events?
Key speakers include Dr. Keith Cummings, CFO, Dr. Éric Lefebvre, CMO, and Dr. Bernard Coulie, President and CEO.
Are the live webcasts accessible to the public?
Yes, the live webcasts will be available through the Pliant Therapeutics Investor Relations webpage, and recordings will be archived for 30 days.
What is the primary indication for Pliant’s lead drug bexotegrast?
Bexotegrast is primarily being developed for the treatment of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
How can I stay updated on Pliant Therapeutics’ progress?
You can stay updated by visiting their official website and following them on social media platforms.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Coiled Tubing Market to Reach $6.5 Billion Driven by Innovation
- Challenges and Advances in Sickle Cell Disease Treatments
- Comun Expands Services with New Funding for Immigrant Support
- NewtekOne, Inc. CEO Barry Sloane to Attend Key Conference
- Blink Charging Announces Leadership Transition
- AUGA group, AB Investor Conference Webinar Details
- Public Opening Position Disclosure by Rathbones Group Plc
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- Pinpoint Digital, LLC Transforms Online Presence with New Website
- Verizon Home Internet Claims Reviewed by NAD